AdaptHealth (AHCO) Q2 2024 earnings summary

Executive summary

• Net revenue for Q2 2024 was $806 million, up 1.6% year-over-year, driven by growth in sleep and respiratory businesses, while diabetes revenue declined; net income attributable to shareholders was $19.44 million, a 39% increase from Q2 2023.

• Adjusted EBITDA for Q2 2024 was $165.3 million (20.5% margin), down from $171.0 million (21.6% margin) in Q2 2023.

• Free cash flow for Q2 2024 was $116.7 million, a significant increase from $3.7 million in Q2 2023, aided by improved collections and temporary funding assistance.

• Leadership changes included the appointment of Suzanne Foster as CEO and Dr. Philip Parks as EVP of Strategy and Healthcare Innovation.

• Management is focused on standardizing processes, investing in talent and technology, and leveraging AI and automation for efficiency and growth.

Financial highlights

• Sales revenue was $516.41 million, rental revenue $258.33 million, and capitated revenue $31.24 million for Q2 2024.

• Sleep revenue grew 6.5% to $322.4 million; sleep resupply census reached over 1.6 million patients.

• Diabetes revenue was $151.2 million, down 10.5% year-over-year due to payer and channel shifts.

• Respiratory revenue increased 4.6% to $161.2 million, with market share gains and new patient onboarding.

• Free cash flow for Q2 2024 was $116.7 million, exceeding the $94 million target.

Outlook and guidance

• Q3 revenue expected to be flat sequentially, with adjusted EBITDA margin at 20.0% and free cash flow of at least $30 million.

• Full-year 2024 guidance: net revenue $3.255–$3.315 billion, adjusted EBITDA $660–$700 million, free cash flow $160–$180 million.

• Diabetes revenue expected to rebound in the second half, with a strong Q4 due to seasonality.

• Management expects operating cash flows, existing cash, and available credit to be sufficient for at least the next twelve months.

• Participation in the Optum Temporary Funding Assistance Program provided $39.6 million in liquidity, with repayment expected by year-end.